Venture Capital for Genomics Sinks Amid Upswing in Overall Biotech Funding in 2002 | GenomeWeb

NEW YORK, Jan. 3 - While private investment in biotechnology rose in 2002, the growth marked a shift to funding drug discovery companies at the expense of genomics and tool concerns, according to an audit by a private-equity tracking firm.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.